Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
Thoracic Cancer|January 30, 2018
Evaluation of calculating carboplatin dosage in carboplatin-pemetrexed therapy as the first-line therapy for Chinese patients with advanced lung adenocarcinomaYixiang Zhu, Puyuan Xing, Shouzheng Wang, et al.
Targeted Oncology|May 25, 2019
Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with OsimertinibYuxin Mu, Xuezhi Hao, Ke Yang, et al.
Thoracic Cancer|July 2, 2022
Disease monitoring of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer patients treated with tyrosine kinase inhibitors via EGFR status in circulating tumor DNAYan Li, Ziyi Xu, Shouzheng Wang, et al.
Echocardiography (Mount Kisco, N.Y.)|June 20, 2018
Feasibility and effectiveness of percutaneous balloon mitral valvuloplasty under echocardiographic guidance onlyYao Liu, Gai-Li Guo, Bin Wen, et al.
Thoracic Cancer|September 7, 2021
Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinomaShouzheng Wang, Tongji Xie, Xuezhi Hao, et al.
Reviews in Cardiovascular Medicine|July 30, 2024
Feasibility of a Percutaneous and Non-Fluoroscopic Procedure for Transcatheter Mitral Valve Edge-to-Edge RepairShuyi Feng, Pengxu Kong, Shouzheng Wang, et al.
Reviews in Cardiovascular Medicine|October 15, 2025
Global, Regional, and National Time Trends in Mortality for Ischemic Heart Disease, 1990-2019: An Age-Period-Cohort Analysis for the Global Burden of Disease 2019 StudyXuanqi An, Ning Zhou, Jing Xie, et al.
Thoracic Cancer|September 22, 2021
Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutationsTeng Li, Shouzheng Wang, Jianming Ying, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|October 18, 2023
The cardiovascular disease burden attributable to low physical activity in the Western Pacific Region, 1990-2019: an age-period-cohort analysis of the Global Burden of Disease studyZeye Liu, Ziping Li, Jing Xie, et al.
Cancer Management and Research|March 8, 2022
Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese PatientsZiyi Xu, Xuezhi Hao, Qi Wang, et al.
Pageof 8